Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why
Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth?
Allogene Therapeutics Announces Participation in December Investor Conferences
Allogene Therapeutics Highlights Presentation Of ALLO-329 Preclinical Data At American College of Rheumatology Convergence 2024
Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Cuts Target Price to $9
Piper Sandler Maintains Overweight on Allogene Therapeutics, Lowers Price Target to $9